Typhoid Fever - Pipeline Review, Q2 2011

Summary

Company’s, Typhoid Fever - Pipeline Review, Q2 2011, provides an overview of the Typhoid Fever therapeutic pipeline. This report provides information on the therapeutic development for Typhoid Fever, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Typhoid Fever. Typhoid Fever - Pipeline Review, Q2 2011 is built using data and information sourced from Company’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Company’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Typhoid Fever.
- A review of the Typhoid Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Typhoid Fever pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Typhoid Fever.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Typhoid Fever pipeline depth and focus of Typhoid Fever therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 4
List of Figures 5
Introduction 6
Company Report Coverage 6
Typhoid Fever Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Typhoid Fever 8
Typhoid Fever Therapeutics under Development by Companies 10
Typhoid Fever Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Typhoid Fever Therapeutics - Products under Development by Companies 15
Typhoid Fever Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Typhoid Fever Therapeutics Development 17
Emergent BioSolutions Inc. 17
Nanotherapeutics, Inc. 17
Novartis AG 18
Celldex Therapeutics, Inc. 18
Typhoid Fever - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
Ty800 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
GelVac - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Salmonella Typhi Vi O-acetyl Pectin-rEPA Conjugate Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CVD 909 + Typhim Vi - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Vi-rEPA(2) Conjugate Vaccine + DTP Vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Typhella - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Typhella - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Vi-CRM197 Glycoconjugated Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
FB-1811 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Typhoid Fever Therapeutics – Drug Profile Updates 37
Typhoid Fever - Featured News 38
Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate 38
Apr 01, 2008: AVANT Meets Primary Endpoints For Ty800 Vaccine In Phase II Study 38
Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine 39
Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine 39
Aug 30, 2005: Emergent Biosolutions Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 42
Contact Us 42
Disclaimer 42

List of Tables

Number of Products Under Development for Typhoid Fever, Q2 2011 8
Products under Development for Typhoid Fever – Comparative Analysis, Q2 2011 9
Number of Products under Development by Companies, Q2 2011 10
Number of Products under Investigation by Universities/Institutes, Q2 2011 11
Comparative Analysis by Mid Clinical Stage Development, Q2 2011 12
Comparative Analysis by Early Clinical Stage Development, Q2 2011 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011 14
Products under Development by Companies, Q2 2011 15
Products under Investigation by Universities/Institutes, Q2 2011 16
Emergent BioSolutions Inc., 2011 17
Nanotherapeutics, Inc., 2011 17
Novartis AG, 2011 18
Celldex Therapeutics, Inc., 2011 18
Assessment by Monotherapy Products, Q2 2011 19
Assessment by Combination Products 20
Assessment by Stage and Route of Administration, Q2 2011 22
Assessment by Molecule Type, Q2 2011 24
Typhoid Fever Therapeutics – Drug Profile Updates 37

List of Figures

Number of Products under Development for Typhoid Fever, Q2 2011 8
Products under Development for Typhoid Fever – Comparative Analysis, Q2 2011 9
Products under Development by Companies, Q2 2011 10
Products under Investigation by Universities/Institutes, Q2 2011 11
Mid Clinical Stage Products, Q2 2011 12
Early Clinical Stage Products, Q2 2011 13
Discovery and Pre-Clinical Stage Products, Q2 2011 14
Assessment by Monotherapy Products, Q2 2011 19
Assessment by Combination Products, Q2 2011 20
Assessment by Route of Administration, Q2 2011 21
Assessment by Stage and Route of Administration, Q2 2011 22
Assessment by Molecule Type, Q2 2011 23
Assessment by Stage and Molecule Type, Q2 2011 24